Additional Products


Through its former wholly-owned subsidiary, NX Development Corp. (“NXDC”), NX PharmaGen fostered the FDA approval and US launch of an important new imaging tool for brain tumor patients.   Gleolan is a fluorescence-guided resection imaging agent for malignant glioma cases.  NXDC was acquired in 2018.